Louiza S. Velentzis

Dr. Louiza S. Velentzis


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2011 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
LVLouiza S. Velentzis
Louiza S. Velentzis
MKMohammed R. Keshtgar
Mohammed R. Keshtgar
JWJayne Woodside
Jayne Woodside
ALAnthony J. Leathem
Anthony J. Leathem
ATAnn Titcomb
Ann Titcomb
MCMarie M. Cantwell
Marie M. Cantwell

20 December 2018 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
CNCarolyn Nickson
Carolyn Nickson
PPPietro Procopio
Pietro Procopio
LVLouiza S. Velentzis
Louiza S. Velentzis
SCSarah Carr
Sarah Carr
LDLisa Devereux
Lisa Devereux
ICian Campbell
ian Campbell
There is a growing interest in delivering more personalised, risk-based breast cancer screening protocols. This requires population-level validation of practical models that can stratify women into breast cancer risk groups. Few studies have evaluated the Gail model (NCI Breast Cancer Risk Assessment Tool) in a population screening setting; we validated this tool in a large, screened population. We used data from 40,158 women aged 50–69 years (via the lifepool cohort) participating in Australia’s BreastScreen programme. We investigated the association between Gail scores and future invasive breast cancer, comparing observed and expected outcomes by Gail score ranked groups. We also used machine learning to rank Gail model input variables by importance and then assessed the incremental benefit in risk prediction obtained by adding variables in order of diminishing importance. Over a median of 4.3 years, the Gail model predicted 612 invasive breast cancers compared with 564 observed cancers (expected/observed (E/O) = 1.09, 95% confidence interval (CI) 1.00–1.18). There was good agreement across decile groups of Gail scores (χ2 = 7.1, p = 0.6) although there was some overestimation of cancer risk in the top decile of our study group (E/O = 1.65, 95% CI 1.33–2.07). Women in the highest quintile (Q5) of Gail scores had a 2.28-fold increased risk of breast cancer (95% CI 1.73–3.02, p < 0.0001) compared with the lowest quintile (Q1). Compared with the median quintile, women in Q5 had a 34% increased risk (95% CI 1.06–1.70, p = 0.014) and those in Q1 had a 41% reduced risk (95% CI 0.44–0.79, p < 0.0001). Similar patterns were observed separately for women aged 50–59 and 60–69 years. The model’s overall discrimination was modest (area under the curve (AUC) 0.59, 95% CI 0.56–0.61). A reduced Gail model excluding information on ethnicity and hyperplasia was comparable to the full Gail model in terms of correctly stratifying women into risk groups. This study confirms that the Gail model (or a reduced model excluding information on hyperplasia and ethnicity) can effectively stratify a screened population aged 50–69 years according to the risk of future invasive breast cancer. This information has the potential to enable more personalised, risk-based screening strategies that aim to improve the balance of the benefits and harms of screening.

23 March 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LVLouiza S. Velentzis
Louiza S. Velentzis
EBEmily Banks
Emily Banks
FSFreddy Sitas
Freddy Sitas
USUsha Salagame
Usha Salagame
ETEng Hooi Tan
Eng Hooi Tan
KCKaren Canfell
Karen Canfell
Menopausal Hormone Therapy (MHT) use in Australia fell by 55% from 2001 to 2005, following the release of large-scale findings on its risks and benefits. Comprehensive national data, including information on overall prevalence of MHT use as well as information on duration of use in Australia have not been reported since the 2004–5 National Health Survey, when 11% of women aged 45+ years were estimated to be current MHT users. No national data are available on prevalence of use of “bioidentical” hormone therapy (BHT). The objective of this study was to determine recent prevalence of MHT and BHT use. A cross-sectional, national, age-stratified, population survey was conducted in 2013. Eligible women, aged 50–69 years, resident in Australia were randomly sampled in 5-year age groups from the Medicare enrolment database (Australia’s universal health scheme). The response rate was 22% based on return of completed questionnaires, and analyses were restricted to 4,389 women within the specified age range. The estimated population-weighted prevalence of current use of MHT was 13% (95%CI 12–14), which was broadly similar to the previously reported national figures in 2004–5, suggesting that the use of MHT in Australia has largely stabilised over the past decade. A total of 39% and 20% of current-users with an intact uterus reported use of oestrogen-progestagen MHT and oestrogen-only MHT, respectively, whereas 77% of hysterectomised current-users used oestrogen-only MHT. Almost three-quarters of current-users [population-weighted prevalence 9% (95%CI 8–10)] had used MHT for ≥5 years. In regard to BHT, estimated population-weighted prevalence of ever use was 6% (95%CI 6–7) and 2% (95%CI 2–3) for current use. The population-weighted prevalence of MHT and BHT combined, in current users in their fifties and sixties was 15% (95%CI 14–16). These data provide a recent national “snapshot” of Australian women’s use of both conventional MHT and of BHT.

12 August 2017 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
LVLouiza S. Velentzis
Louiza S. Velentzis
MCMichael Caruana
Michael Caruana
KSKate T. Simms
Kate T. Simms
JLJie‐Bin Lew
Jie‐Bin Lew
JSJufang Shi
Jufang Shi
KCKaren Canfell
Karen Canfell
Primary HPV screening enables earlier diagnosis of cervical lesions compared to cytology, however, its effect on the risk of treatment and adverse obstetric outcomes has not been extensively investigated. We estimated the cumulative lifetime risk (CLR) of cervical cancer and excisional treatment, and change in adverse obstetric outcomes in HPV unvaccinated women and cohorts offered vaccination (>70% coverage in 12–13 years) for the Australian cervical screening program. Two‐yearly cytology screening (ages 18–69 years) was compared to 5‐yearly primary HPV screening with partial genotyping for HPV16/18 (ages 25–74 years). A dynamic model of HPV transmission, vaccination, cervical screening and treatment for precancerous lesions was coupled with an individual‐based simulation of obstetric complications. For cytology screening, the CLR of cervical cancer diagnosis, death and treatment was estimated to be 0.649%, 0.198% and 13.4% without vaccination and 0.182%, 0.056% and 6.8%, in vaccinated women, respectively. For HPV screening, relative reductions of 33% and 22% in cancer risk for unvaccinated and vaccinated women are predicted, respectively, compared to cytology. Without the implementation of vaccination, a 4% increase in treatment risk for HPVversuscytology screening would have been expected, implying a possible increase in pre‐term delivery (PTD) and low birth weight (LBW) events of 19 to 35 and 14 to 37, respectively, per 100,000 unvaccinated women. However, in vaccinated women, treatment risk will decrease by 13%, potentially leading to 4 to 41 fewer PTD events and from 2 more to 52 fewer LBW events per 100,000 vaccinated women. In unvaccinated women in cohorts offered vaccination as 12–13 year olds, no change to lifetime treatment risk is expected with HPV screening. In unvaccinated women in cohorts offered vaccination as 12–13 year olds, no change to lifetime treatment risk is expected with HPV screening. HPV screening starting at age 25 in populations with high vaccination coverage, is therefore expected to both improve the benefits (further decrease risk of cervical cancer) and reduce the harms (reduce treatments and possible obstetric complications) associated with cervical cancer screening.

25 February 2019 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
MAMaria E. Arriaga
Maria E. Arriaga
CVClaire Vajdic
Claire Vajdic
KCKaren Canfell
Karen Canfell
RMRobert J. MacInnis
Robert J. MacInnis
EBEmily Banks
Emily Banks
MLMaarit A. Laaksonen
Maarit A. Laaksonen

9 February 2023 in Cancers
Verified
Journal Article
Open access
PDF file
LVLouiza S. Velentzis
Louiza S. Velentzis
VFVictoria Freeman
Victoria Freeman
DCDenise Campbell
Denise Campbell
SHSuzanne Hughes
Suzanne Hughes
QLQingwei Luo
Qingwei Luo
CNCarolyn Nickson
Carolyn Nickson
Background: The benefits and harms of breast screening may be better balanced through a risk-stratified approach. We conducted a systematic review assessing the accuracy of questionnaire-based risk assessment tools for this purpose. Methods: Population: asymptomatic women aged ≥40 years; Intervention: questionnaire-based risk assessment tool (incorporating breast density and polygenic risk where available); Comparison: different tool applied to the same population; Primary outcome: breast cancer incidence; Scope: external validation studies identified from databases including Medline and Embase (period 1 January 2008–20 July 2021). We assessed calibration (goodness-of-fit) between expected and observed cancers and compared observed cancer rates by risk group. Risk of bias was assessed with PROBAST. Results: Of 5124 records, 13 were included examining 11 tools across 15 cohorts. The Gail tool was most represented (n = 11), followed by Tyrer-Cuzick (n = 5), BRCAPRO and iCARE-Lit (n = 3). No tool was consistently well-calibrated across multiple studies and breast density or polygenic risk scores did not improve calibration. Most tools identified a risk group with higher rates of observed cancers, but few tools identified lower-risk groups across different settings. All tools demonstrated a high risk of bias. Conclusion: Some risk tools can identify groups of women at higher or lower breast cancer risk, but this is highly dependent on the setting and population.